22 results on '"Potter, Shelley"'
Search Results
2. Outcomes of Women Undergoing Mastectomy for Unilateral Breast Cancer Who Elect to Undergo Contralateral Mastectomy for Symmetry: A Systematic Review
- Author
-
Griffin, Cora, Fairhurst, Katherine, Stables, Imogen, Brunsden, Sam, and Potter, Shelley
- Published
- 2024
- Full Text
- View/download PDF
3. Study protocol for two pilot randomised controlled trials aimed at increasing physical activity using electrically assisted bicycles to enhance prostate or breast cancer survival
- Author
-
Bourne, Jessica E., Foster, Charlie, Forte, Chloe, Aning, Jonathan, Potter, Shelley, Hart, Emma C., and Armstrong, Miranda E. G.
- Published
- 2023
- Full Text
- View/download PDF
4. Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study
- Author
-
Dave, Rajiv V., Elsberger, Beatrix, Taxiarchi, Vicky P., Gandhi, Ashu, Kirwan, Cliona C., Kim, Baek, Camacho, Elizabeth M., Coles, Charlotte E., Copson, Ellen, Courtney, Alona, Horgan, Kieran, Fairbrother, Patricia, Holcombe, Chris, Kirkham, Jamie J., Leff, Daniel R., McIntosh, Stuart A., O’Connell, Rachel, Pardo, Ricardo, Potter, Shelley, Rattay, Tim, Sharma, Nisha, Vidya, Raghavan, and Cutress, Ramsey I.
- Published
- 2023
- Full Text
- View/download PDF
5. Understanding decision-making for and against oncoplastic breast-conserving surgery as an alternative to a mastectomy in early breast cancer: UK ANTHEM qualitative study.
- Author
-
Davies, Charlotte, Conefrey, Carmel, Mills, Nicola, Fairbrother, Patricia, Holcombe, Chris, Whisker, Lisa, Skillman, Joanna, White, Paul, MacMillan, Douglas, Comins, Charles, Hollingworth, William, and Potter, Shelley
- Subjects
MAMMAPLASTY ,LUMPECTOMY ,MASTECTOMY ,BREAST cancer ,DECISION making ,QUALITATIVE research - Abstract
Background: Oncoplastic breast-conserving surgery may allow women with early breast cancer to avoid a mastectomy, but many women undergo more extensive surgery, even when breast-conserving options are offered. The aim of the ANTHEM qualitative study was to explore factors influencing women's surgical decision-making for and against oncoplastic breast-conserving surgery. Methods: Semi-structured interviews were conducted with a purposive sample of women who had received either oncoplastic breast-conserving surgery or a mastectomy with or without immediate breast reconstruction to explore their rationale for procedure choice. Interviews were transcribed verbatim and analysed thematically. Trial registration number: ISRCTN18238549. Results: A total of 27 women from 12 centres were interviewed. Out of these, 12 had chosen oncoplastic breast-conserving surgery and 15 had chosen a mastectomy with or without immediate breast reconstruction. Overwhelmingly, women's decisions were guided by their surgical teams. Decision-making for and against oncoplastic breast-conserving surgery was influenced by three key inter-related factors: perceptions of oncological safety; the importance of maintaining/restoring femininity and body image; and practical issues. Oncological safety was paramount. Women who reported feeling reassured that oncoplastic breast-conserving surgery was oncologically safe were happy to choose this option. Those who were not reassured were more likely to opt for a mastectomy, as a perceived 'safer' option. Most women wished to maintain/restore femininity, with the offer of immediate breast reconstruction essential to make a mastectomy an acceptable option. Practical issues such as the perceived magnitude of the surgery were a lesser concern. Conclusion: Decision-making is complex and heavily influenced by the surgical team. High-quality, accurate information about surgical options, including appropriate reassurance about the short- and long-term oncological safety of oncoplastic breast-conserving surgery is vital if women are to make fully informed decisions. Perceived overestimation of the oncological benefits of a mastectomy and a lack of awareness of the potential short- and long-term issues associated with breast reconstruction raise concerns about the quality of the information provided to women making decisions about their options and the degree to which their decisions are fully informed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Overall survival after mastectomy versus breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer: meta-analysis.
- Author
-
Rajan, Kiran K, Fairhurst, Katherine, Birkbeck, Beth, Novintan, Shonnelly, Wilson, Rebecca, Savović, Jelena, Holcombe, Chris, and Potter, Shelley
- Subjects
LUMPECTOMY ,RADIOTHERAPY ,BREAST cancer ,MASTECTOMY ,OVERALL survival ,NEOADJUVANT chemotherapy - Abstract
Background Breast-conserving surgery with adjuvant radiotherapy and mastectomy are currently offered as equivalent surgical options for early-stage breast cancer based on RCTs from the 1970s and 1980s. However, the treatment of breast cancer has evolved and recent observational studies suggest a survival advantage for breast-conserving surgery with adjuvant radiotherapy. A systematic review and meta-analysis was undertaken to summarize the contemporary evidence regarding survival after breast-conserving surgery with adjuvant radiotherapy versus mastectomy for women with early-stage breast cancer. Methods A systematic search of MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL), and Embase that identified studies published between 1 January 2000 and 18 December 2023 comparing overall survival after breast-conserving surgery with adjuvant radiotherapy versus mastectomy for patients with unilateral stage 1–3 breast cancer was undertaken. The main exclusion criteria were studies evaluating neoadjuvant chemotherapy, rare breast cancer subtypes, and specific breast cancer populations. The ROBINS-I tool was used to assess risk of bias, with the overall certainty of evidence assessed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) tool. Studies without critical risk of bias were included in a quantitative meta-analysis. Results From 11 750 abstracts, 108 eligible articles were identified, with one article including two studies; 29 studies were excluded from the meta-analysis due to an overall critical risk of bias, 42 studies were excluded due to overlapping study populations, and three studies were excluded due to reporting incompatible results. A total of 35 observational studies reported survival outcomes for 909 077 patients (362 390 patients undergoing mastectomy and 546 687 patients undergoing breast-conserving surgery with adjuvant radiotherapy). The pooled HR was 0.72 (95% c.i. 0.68 to 0.75, P < 0.001), demonstrating improved overall survival for patients undergoing breast-conserving surgery with adjuvant radiotherapy. The overall certainty of the evidence was very low. Conclusion This meta-analysis provides evidence suggesting a survival advantage for women undergoing breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer compared with mastectomy. Although these results should be interpreted with caution, they should be shared with patients to support informed surgical decision-making. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Long-term patient-reported outcomes of immediate breast reconstruction after mastectomy for breast cancer: population-based cohort study.
- Author
-
Johnson, Leigh, White, Paul, Jeevan, Ranjeet, Browne, John, Gulliver-Clarke, Carmel, O'Donoghue, Joe, Mohiuddin, Syed, Hollingworth, William, Fairbrother, Patricia, MacKenzie, Mairead, Holcombe, Chris, and Potter, Shelley
- Subjects
MAMMAPLASTY ,PATIENT reported outcome measures ,BREAST cancer ,MASTECTOMY ,COHORT analysis - Published
- 2023
- Full Text
- View/download PDF
8. Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study
- Author
-
Dave, Rajiv, Elsberger, Beatrix, Taxiarchi, Paraskevi, Gandhi, Ashu, Kirwan, Cliona, Kim, Baek, Camacho, Liz, Coles, Charlotte, Copson, Ellen, Courtney, Alona, Horgan, Kieran, Fairbrother, Patricia, Holcombe, Chris, Kirkham, Jamie, Leff, Daniel, McIntosh, Stuart, O’Connell, Rachel, Pardo, Ricardo, Potter, Shelley, Rattay, Tim, Sharma, Nisha, Vidya, Raghavan, and Cutress, Ramsey
- Subjects
Breast cancer ,SDG 3 - Good Health and Well-being ,COVID-19 ,Neoadjuvant endocrine therapy ,Bridging endocrine therapy - Abstract
Purpose: The B-MaP-C study investigated changes to breast cancer care that were necessitated by the COVID-19 pandemic. Here we present a follow-up analysis of those patients commenced on bridging endocrine therapy (BrET), whilst they were awaiting surgery due to reprioritisation of resources.Methods: This multicentre, multinational cohort study recruited 6045 patients from the UK, Spain and Portugal during the peak pandemic period (Feb-July 2020). Patients on BrET were followed up to investigate the duration of, and response to, BrET. This included changes in tumour size to reflect downstaging potential, and changes in cellular proliferation (Ki67), as a marker of prognosis.Results: 1094 patients were prescribed BrET, over a median period of 53 days (IQR 32-81 days). The majority of patients (95.6%) had strong ER expression (Allred score 7-8/8). Very few patients required expedited surgery, due to lack of response (1.2%) or due to lack of tolerance/compliance (0.8%). There were small reductions in median tumour size after 3 months' treatment duration; median of 4 mm [IQR - 20, 4]. In a small subset of patients (n = 47), a drop in cellular proliferation (Ki67) occurred in 26 patients (55%), from high (Ki67 ≥ 10%) to low (< 10%), with at least one month's duration of BrET.Discussion: This study describes real-world usage of pre-operative endocrine therapy as necessitated by the pandemic. BrET was found to be tolerable and safe. The data support short-term (≤ 3 months) usage of pre-operative endocrine therapy. Longer-term use should be investigated in future trials.
- Published
- 2023
9. Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study
- Author
-
Dave, Rajiv V, Elsberger, Beatrix, Taxiarchi, Vicky P, Gandhi, Ashu, Kirwan, Cliona C, Kim, Baek, Camacho, Elizabeth M, Coles, Charlotte E, Copson, Ellen, Courtney, Alona, Horgan, Kieran, Fairbrother, Patricia, Holcombe, Chris, Kirkham, Jamie J, Leff, Daniel R, McIntosh, Stuart A, O'Connell, Rachel, Pardo, Ricardo, Potter, Shelley, Rattay, Tim, Sharma, Nisha, Vidya, Raghavan, Cutress, Ramsey I, B-MaP-C Study Collaborative, Dave, Rajiv V [0000-0001-6827-8090], and Apollo - University of Cambridge Repository
- Subjects
Cohort Studies ,Ki-67 Antigen ,Breast cancer ,Humans ,COVID-19 ,Female ,Breast Neoplasms ,Neoadjuvant endocrine therapy ,Prognosis ,Pandemics ,Bridging endocrine therapy ,Neoadjuvant Therapy - Abstract
PURPOSE: The B-MaP-C study investigated changes to breast cancer care that were necessitated by the COVID-19 pandemic. Here we present a follow-up analysis of those patients commenced on bridging endocrine therapy (BrET), whilst they were awaiting surgery due to reprioritisation of resources. METHODS: This multicentre, multinational cohort study recruited 6045 patients from the UK, Spain and Portugal during the peak pandemic period (Feb-July 2020). Patients on BrET were followed up to investigate the duration of, and response to, BrET. This included changes in tumour size to reflect downstaging potential, and changes in cellular proliferation (Ki67), as a marker of prognosis. RESULTS: 1094 patients were prescribed BrET, over a median period of 53 days (IQR 32-81 days). The majority of patients (95.6%) had strong ER expression (Allred score 7-8/8). Very few patients required expedited surgery, due to lack of response (1.2%) or due to lack of tolerance/compliance (0.8%). There were small reductions in median tumour size after 3 months' treatment duration; median of 4 mm [IQR - 20, 4]. In a small subset of patients (n = 47), a drop in cellular proliferation (Ki67) occurred in 26 patients (55%), from high (Ki67 ≥ 10%) to low (< 10%), with at least one month's duration of BrET. DISCUSSION: This study describes real-world usage of pre-operative endocrine therapy as necessitated by the pandemic. BrET was found to be tolerable and safe. The data support short-term (≤ 3 months) usage of pre-operative endocrine therapy. Longer-term use should be investigated in future trials.
- Published
- 2023
10. Localization Techniques for Non-Palpable Breast Lesions: Current Status, Knowledge Gaps, and Rationale for the MELODY Study (EUBREAST-4/iBRA-NET, NCT 05559411).
- Author
-
Banys-Paluchowski, Maggie, Kühn, Thorsten, Masannat, Yazan, Rubio, Isabel, de Boniface, Jana, Ditsch, Nina, Karadeniz Cakmak, Güldeniz, Karakatsanis, Andreas, Dave, Rajiv, Hahn, Markus, Potter, Shelley, Kothari, Ashutosh, Gentilini, Oreste Davide, Gulluoglu, Bahadir M., Lux, Michael Patrick, Smidt, Marjolein, Weber, Walter Paul, Aktas Sezen, Bilge, Krawczyk, Natalia, and Hartmann, Steffi
- Subjects
CLINICAL pathology equipment ,COMPUTER-assisted surgery ,MAGNETS ,ULTRASONIC imaging ,PROFESSIONS ,ATTITUDES of medical personnel ,INTRAOPERATIVE care ,TREATMENT effectiveness ,PATIENTS' attitudes ,RADIOACTIVE elements ,RADIO waves ,BREAST tumors - Abstract
Simple Summary: Most breast cancers are small and can be treated using breast-conserving surgery. Since these tumors are non-palpable, they require a localization step that helps the surgeon to decide which tissue needs to be removed. The oldest localization technique is a guidewire placed into the tumor before surgery, usually using ultrasound or mammography. Afterwards, the surgeon removes the tissue around the wire tip. However, this technique has several disadvantages: It can cause the patient discomfort, requires a radiologist or another professional specialized in breast diagnostics to perform the procedure shortly before surgery, and 15–20% of patients need a second surgery to completely remove the tumor. Therefore, new techniques have been developed but most of them have not yet been examined in large, prospective, multicenter studies. In this review, we discuss all available techniques and present the MELODY study that will investigate their safety, with a focus on patient, surgeon, and radiologist preference. Background: Surgical excision of a non-palpable breast lesion requires a localization step. Among available techniques, wire-guided localization (WGL) is most commonly used. Other techniques (radioactive, magnetic, radar or radiofrequency-based, and intraoperative ultrasound) have been developed in the last two decades with the aim of improving outcomes and logistics. Methods: We performed a systematic review on localization techniques for non-palpable breast cancer. Results: For most techniques, oncological outcomes such as lesion identification and clear margin rate seem either comparable with or better than for WGL, but evidence is limited to small cohort studies for some of the devices. Intraoperative ultrasound is associated with significantly higher negative margin rates in meta-analyses of randomized clinical trials (RCTs). Radioactive techniques were studied in several RCTs and are non-inferior to WGL. Smaller studies show higher patient preference towards wire-free localization, but little is known about surgeons' and radiologists' attitudes towards these techniques. Conclusions: Large studies with an additional focus on patient, surgeon, and radiologist preference are necessary. This review aims to present the rationale for the MELODY (NCT05559411) study and to enable standardization of outcome measures for future studies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Referral patterns, cancer diagnoses, and waiting times after introduction of two week wait rule for breast cancer: prospective cohort study
- Author
-
Potter, Shelley, Govindarajulu, Sasi, Shere, Mike, Braddon, Fiona, Curran, Geoffrey, Greenwood, Rosemary, Sahu, Ajay K, and Cawthorn, Simon J
- Published
- 2007
12. Results of shared learning of a new magnetic seed localisation device – A UK iBRA-NET breast cancer localisation study.
- Author
-
Morgan, Jenna L., Bromley, Hannah L., Dave, Rajiv V., Masannat, Yazan, Masudi, Tahir, Mylvaganam, Senthurun, Elgammal, Suzanne, Barnes, Nicola, Down, Sue, Holcombe, Chris, Potter, Shelley, Gardiner, Matthew D., Maxwell, Anthony J., Somasundaram, Santosh K., Sami, Amtul, Kirwan, Cliona, and Harvey, James
- Subjects
BREAST cancer ,BREAST surgery ,PATIENT selection ,EDUCATIONAL outcomes ,THEMATIC analysis ,MAMMAPLASTY ,FORMATIVE tests - Abstract
Shared learning is imperative in the assessment and safe implementation of new healthcare interventions. Magnetic seeds (Magseed®) potentially offer logistical benefit over wire localisation for non-palpable breast lesions but few data exist on outcomes comparing these techniques. A national registration study (iBRA-NET) was conducted to collate device outcomes. In order to share learning, thematic analysis was conducted to ascertain early clinical experiences of Magseed® and wire guided localisation and explore how learning events may be applied to improve clinical outcomes. A qualitative study of 27 oncoplastic surgeons, radiologists and physicians was conducted in January 2020 to ascertain the feasibility and challenges associated with Magseed® versus wire breast localisation surgery. Four focus groups were asked to discuss experiences, concerns and shared learning outcomes which were tabulated and analysed thematically. Three key themes were identified comparing Magseed® and wire localisation of breast lesions relating to preoperative, intraoperative and postoperative learning outcomes. Percutaneous Magseed® detection, instrument interference and potential seed or wire dislodgement were the most common issues identified. Clinician experience suggested Magseed® index lesion identification was non-inferior to wire placement and improved the patient pathway in terms of scheduling and multi-site insertion. Prospective shared learning suggested Magseed® offered additional non-clinical benefits over wire localisation, improving the efficiency of the patient pathway. Recommendations for improving breast localisation technique, appropriate patient selection and clinical practice through shared learning are discussed that may aid other surgeons in the adoption of this relatively new technique. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study.
- Author
-
Fatayer, Hiba, O'Connell, Rachel L., Bannon, Finian, Coles, Charlotte E., Copson, Ellen, Cutress, Ramsey I., Dave, Rajiv V., Gardiner, Matthew D., Grayson, Margaret, Holcombe, Christopher, Irshad, Sheeba, Irwin, Gareth W., O'Brien, Ciara, Palmieri, Carlo, Shaaban, Abeer M., Sharma, Nisha, Singh, Jagdeep K., Whitehead, Ian, Potter, Shelley, and McIntosh, Stuart A.
- Subjects
NEOADJUVANT chemotherapy ,BREAST cancer ,TUMOR classification - Published
- 2022
- Full Text
- View/download PDF
14. The MARECA (national study of management of breast cancer locoregional recurrence and oncological outcomes) study: National practice questionnaire of United Kingdom multi-disciplinary decision making.
- Author
-
Morgan, Jenna L., Cheng, Vinton, Barry, Peter A., Copson, Ellen, Cutress, Ramsey I., Dave, Rajiv, Elsberger, Beatrix, Fairbrother, Patricia, Hartup, Sue, Hogan, Brian, Horgan, Kieran, Kirwan, Cliona C., McIntosh, Stuart A., O'Connell, Rachel L., Patani, Neill, Potter, Shelley, Rattay, Tim, Sheehan, Lisa, Wyld, Lynda, and Kim, Baek
- Subjects
CANCER relapse ,TRIPLE-negative breast cancer ,BREAST cancer ,SENTINEL lymph node biopsy ,DECISION making ,RADIONUCLIDE imaging - Abstract
Evidence based guidelines for the optimal management of breast cancer locoregional recurrence (LRR) are limited, with potential for variation in clinical practice. This national practice questionnaire (NPQ) was designed to establish the current practice of UK breast multidisciplinary teams (MDTs) regarding LRR management. UK breast units were invited to take part in the MARECA study MDT NPQ. Scenario-based questions were used to elicit preference in pre-operative staging investigations, surgical management, and adjuvant therapy. 822 MDT members across 42 breast units (out of 144; 29%) participated in the NPQ (February–August 2021). Most units (95%) routinely performed staging CT scan, but bone scan was selectively performed (31%). For patients previously treated with breast conserving surgery (BCS) and radiotherapy, few units (7%) always/usually offered repeat BCS. However, in the absence of radiotherapy, most units (90%) always/usually offered repeat BCS. For patients presenting with isolated local recurrence following previous BCS and SLNB (sentinel lymph node biopsy), most units (95%) advocated repeat SLNB. Where SLNs could not be identified, 86% proceeded to a four-node axillary sampling procedure. For ER positive, HER2 negative, node negative local recurrence, 10% of units always/usually offered chemotherapy. For ER positive, HER2 negative, node positive local recurrence, this recommendation increased to 64%. For triple negative breast cancer local recurrence, 90% of units always/usually offered chemotherapy. This survey has highlighted where consistencies and variations exist in the multidisciplinary management of breast cancer LRR. However, further research is required to determine how these management patterns influence patient outcomes, which will further refine optimal treatment pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy.
- Author
-
Weber, Walter Paul, Shaw, Jane, Pusic, Andrea, Wyld, Lynda, Morrow, Monica, King, Tari, Mátrai, Zoltán, Heil, Jörg, Fitzal, Florian, Potter, Shelley, Rubio, Isabel T., Cardoso, Maria-Joao, Gentilini, Oreste Davide, Galimberti, Viviana, Sacchini, Virgilio, Rutgers, Emiel J.T., Benson, John, Allweis, Tanir M., Haug, Martin, and Paulinelli, Regis R.
- Subjects
MAMMAPLASTY ,MASTECTOMY ,CLINICAL trials ,RADIOTHERAPY ,OPERATIVE surgery - Abstract
Demand for nipple- and skin- sparing mastectomy (NSM/SSM) with immediate breast reconstruction (BR) has increased at the same time as indications for post-mastectomy radiation therapy (PMRT) have broadened. The aim of the Oncoplastic Breast Consortium initiative was to address relevant questions arising with this clinically challenging scenario. A large global panel of oncologic, oncoplastic and reconstructive breast surgeons, patient advocates and radiation oncologists developed recommendations for clinical practice in an iterative process based on the principles of Delphi methodology. The panel agreed that surgical technique for NSM/SSM should not be formally modified when PMRT is planned with preference for autologous over implant-based BR due to lower risk of long-term complications and support for immediate and delayed-immediate reconstructive approaches. Nevertheless, it was strongly believed that PMRT is not an absolute contraindication for implant-based or other types of BR, but no specific recommendations regarding implant positioning, use of mesh or timing were made due to absence of high-quality evidence. The panel endorsed use of patient-reported outcomes in clinical practice. It was acknowledged that the shape and size of reconstructed breasts can hinder radiotherapy planning and attention to details of PMRT techniques is important in determining aesthetic outcomes after immediate BR. The panel endorsed the need for prospective, ideally randomised phase III studies and for surgical and radiation oncology teams to work together for determination of optimal sequencing and techniques for PMRT for each patient in the context of BR • Autologous breast reconstruction is increasingly preferred over implants in the setting of radiation therapy. • Use of patient-reported outcomes is endorsed. • Shape and size of reconstructed breasts can hinder radiotherapy planning. • There is a need for randomised phase III trials. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Exploring women’s experiences of implant loss after immediate implant-based breast reconstruction:A qualitative study
- Author
-
Mahoney, Bere, Walklet, Elaine, Bradley, Eleanor, Thrush, Steven, Skillman, Joanna, Whisker, Lisa, Barnes, Nicola, Holcombe, Chris, and Potter, Shelley
- Subjects
breast cancer ,implant based reconstruction ,Qualitative study - Abstract
Background: Immediate implant-based breast reconstruction (IBBR) is the most commonly performed reconstructive procedure in the UK but almost one-in-ten women will experience implant loss and reconstructive failure following this technique. Little is known about how implant loss impacts on patients’ quality-of-life. The first phase of the LiBRA study aimed to use qualitative methods to explore women’s experiences of implant loss and develop recommendations to improve care. Methods: Semi-structured interviews were conducted with a purposive sample of women who experienced implant loss following immediate IBBR, for malignancy or risk-reduction across six centres. Interviews explored decision-making for IBBR and experiences of implant loss and support received. Thematic analysis was used to explore the qualitative interview data. Sampling, data collection and analysis were undertaken concurrently and iteratively until data saturation was achieved. Results: Twenty-four patients were interviewed; 19 had surgery for malignancy and 5 for risk-reduction. The median time between implant loss and interview was 42 months (range 22-52). Ten women had undergone secondary reconstruction; two were awaiting surgery and 12 had declined further reconstruction. Three key themes were identified. These were the need for: i) accurate information about the risks and benefits of IBBR; ii) more information about ‘early-warning’ signs of post-operative problems to empower women to seek help; and, iii) better support for patients following implant-loss. Conclusions: Implant loss is a devastating event for many women but better information and support preoperatively and more holistic patient-centred care for patients who develop complications may significantly improve the experience and outcome of care.
- Published
- 2020
17. The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study
- Author
-
O'Connell, Rachel L, Rattay, Tim, Dave, Rajiv V, Trickey, Adam, Skillman, Joanna, Barnes, Nicola LP, Gardiner, Matthew, Harnett, Adrian, Potter, Shelley, Holcombe, Chris, Blazeby, Jane, Conroy, Elizabeth, O'Brien, Ciara, Williamson, Paula, Curnier, Alain, Tadros, Amir, Depasquale, Ivan, Masannat, Yazan A, Smyth, Elizabeth, Fuller, Mairi, Bourne, Roger, Heys, Steven, Hamo, Ishrak, Aloraifi, Fatima, Fopp, Laura, Bali, Radhika, Bache, Sarah, Benyon, Sarah L, Irwin, Michael S, Agrawal, Amit, Malata, Charles M, Murphy, Claire, Misky, Adam, Chicken, Dennis Wayne, Abdullah, Nassreen, Hill, Arnold DK, Cullinane, Carolyn, Irwin, Gareth, McIntosh, Stuart A, Refsum, Sigi, Sloan, Samantha, Mallon, Peter, Sirianni, Chiara, Khattak, Ilyas, Nagachandra, Geerthan, Kiruparan, Pasupathy, Debanth, Debasish, Davey, Simon, Curran, Terry-Ann, Svenning, Matilda, Govindarajulu, Sasirekha, Rayter, Zenon, Ainsworth, Rachel, Cawthorn, Simon, Sahu, Ajay, Wilson, Sherif, Prousskaia, Elena, Accurso, Antonello, Rocco, Nicola, Di Micco, Rosa, Limite, Gennaro, Ceccarino, Raffaele, Liccardo, Raffaele, Coco, Guido, Nizamoglu, Metin, Morgan, Mary, Ramakrishnan, Venkat, Catanuto, Giuseppe, Wilkins, Alex, McManus, Penelope, Kneeshaw, Peter, Grover, Kartikae, Mahapatra, Tapan, Wooler, Brendan, Elahi, Bilal, Ihsan, Naila, Bucknor, Alexandra, Reissis, Dimitris, Hunter, Judith, Wood, Simon, Jallali, Navid, Henry, Francis P, Verjee, Liaquat S, Lee, Jason, Khan, Shazia M, Azmy, Iman, Massey, Julia, Hollywood, Ciaran, Oluwajana, Michael, Bathla, Sonia, Seward, Joanna, Harding-MacKean, Claudia, Lane, Risha, Murali, Kothandaraman, Biswas, Bashishta, Trapszo, Pawel, Seetharam, Seema, Kennedy, Katy, Alder, Louise, Graja, Tomasz, Amin, Khalid, Kokan, Jalal, Roshanlall, Chandeena, Gill, Emma, Kulkarni, Dhananjay, Dixon, JM, Young, Oliver, Saleem, Talha, Biddle, M, Kearns, Marie, Weiler-Mithoff, Eva, Chew, Ben, Malyon, Andy, Scott, John, McGill, David, Mackay, Iain, Bains, Salena, Barrows, Sara, Pilgrim, Simon, Shokuhi, Sheila, Lambert, Kelly, Kenny, Frances, Valassiadou, Kalliope, Kaushik, Monika, Krupa, Jaroslaw, Dragoumis, Dimitris, Ain, Quratul, Lampropoulos, Pavlos, Moss, Sarah, Khalil, Haitham, Haq, Anwar, Balasubramanian, Balapathiran, Charalampou-Dis, Petros, Hamed, Hisham, Kothari, Ashutosh, Kovacs, Tibor, Douek, Michael, Mehmood, Iftikhar, Ray, Biswajit, Adelekan, Matthew, Humphreys, Laura, Tayeh, Salim, Choy, Christina, Parvanta, Laila, Michieletto, Silvia, Saibene, Tania, O'Brien, James, Down, Sue, Downey, Sarah, Pereira, Jerome, Sami, AS, Gvaramadze, Anzors, Jibril, Jibril A, Thekkinkattil, Dinesh, Udayasankar, S, Khawaja, Saira, Shariaha, Yousef, Holt, Simon, James, Ruth, Rizki, Hirah, Kirkpatrick, Katharine, Ravichandran, Duraisamy, Shrestha, Deepak, Barua, Ellora, Akolekar, Deepika, Hamad, Ahmed, Kleidi, Eleftheria, Hignett, Susan, Pope, Vanessa, Naseem, Salma, Isherwood, Jennifer, Soulsby, Rachel, Taylor, Amanda, Chin, Kian, Nguyen, Dai, Guest, Francesca, Thorne, Amanda, Kirchhoff, Chris, Murphy, Declan C, Lo, Michelle, Harcourt, Ruth, Pain, Simon J, Hussien, Maged I, Zechmeister, Katalin, Sassoon, EM, Figus, Andrea, Haywood, Richard M, Ali, Rozina, Alexander, Susanna, Geropantas, Konstantinos, Epurescu, Daniel, Lewis, Rebecca, Fafemi, Oladapo, Gahir, Jasdeep, Gandamihardja, Tasha, Kelsall, Jennett, Muhibullah, Nazli, Otieno, Charlene, Mazari, Fayyaz, Dauria, Marta, Whisker, Lisa, Macmillan, Douglas, Gutteridge, Eleanor, Rasheed, Tuabin, Khout, Hazem, Asgeirsson, Kristjan, McCulley, Stephen, Mariniello, Maria Donatella, Roncella, Manuela, Ghilli, Matteo, Colizzi, Livio, Rossetti, Elena, Marzia, Lo Russo, Fustaino, Loredana, Li, Alessandro Quattrini, Harvey, Kate L, Windle, Rebecca, Remoundos, Dionysios Dennis, Roy, Pankaj, MacLean, Gael, Adwani, Asha, Popa, Elena, Goh, Steven, Shetty, Geeta, Clark, Sarah, Bernaudo, Lorenzo, Agrawal, Avi, Mansfield, Lucy, Tebbal, Sally, Patel, Ashraf, Grassi, Veronica, Pujji, Ojas, Hamnett, Kathryn, Basu, Naren, Granger, Emily, Durbar, Michael, Pikoulas, Panagiotis, Garnsey, Clare, Walker, Philip, Vollermere, Angela J, Michalakis, Ioannis, Jones, Robin, Youssef, Mina, Ives, Charlotte, Masood, Mohammad, Dunn, Julie, Olsen, Sisse, Ferguson, Douglas, Tillett, Rachel, Allan, Anna, Woollard, Alex, Canny, Rebecca, Woollard, Alexander, Mosahebi, Afshin, Hamilton, Stephen, Ghali, Shadi, Marsh, Daniel, Chana, Jagdeep, Sojitra, Nilesh, Younis, Ibby, Rainsbury, Dick, Chand, Natalie, Kalles, Vasileios, Stebbing, Anne, Harris, Kevin, Laws, Siobhan, Tansley, Anne, Mitchell, Geraldine, de Sousa, Emma, Henderson, Julia, Chandrashekar, Mysore, Pereira, Bernadette, Constantinou, Chloe, Elfadl, Dalia, Irakleidis, Foivos, Hernan, Izaro, Byrne, Miriam, To, Natalie, O'Connell, Rachel, Rusby, Jennifer, Barry, Peter, Krupa, Katerine, Allum, William, MacNeill, Fiona, Roche, Nicola, Gui, Gerald, Ramsey, Kelvin, Harris, Paul, James, Stuart, Power, Kieran, Sutton, Richard, McIntosh, Jamie, Laurence, Nicola, MacLennan, Louise, Milligan, Robert, Cain, Henry, Critchley, Adam, O'Donoghue, Joe, Kalra, Loraine, Collis, Nick, Weston-Petrides, Gina, Fiddes, Roanne, Brown, Victoria, Aertssen, Anna, Slade-Sharman, Diana, Khan, Mansoor, McGuiness, Caroline, Amorosi, Vittoria, Fabio, Santanelli di Pompeo, Exarchos, Georgios, Jiwa, Natasha, Hu, Jennifer, Ledwidge, Serena, Johnson, Laura, Peel, Anthony, Dhooma, Naseem, Farrell, Eric, Devane, Liam, Tevlin, Ruth, McDermott, Enda, Prichard, Ruth, Evoy, Denis, Rothwell, Jane, Geraghty, James, Morrison, Colin, Lawlor, Catriona, Langlands, Fiona, Taylor, Lauren, Turton, Philip, Achuthan, Raj, Horgan, Kieran, Mckenzie, Shireen, Hogan, Brian, Lansdown, Mark, Navin, Channegowda, Sherwin, Liz, Mortimer, Caroline, Garg, Neeraj, Adam, Rahma, Arif, Tahera, Kryjak, Zbigniew, Ali, Deedar, Sowdi, Ravi, Fage, Elena, Mylvaganam, Senthurun, Matey, Pilar, Vidya, Raghavan, Sircar, Tapan, Asaad, Oubida, Bhaskar, Pud, Dordea, Matei, Chrysafi, Ada, McCartan, Damian, Dave, Rajiv, Foster, Rachel, Wilson, Rebecca, Okwemba, Sylvia, Majeed, Yousef, Mathen, Vinod, Murphy, John, Barnes, Nicola, Gandhi, Ashu, Harvey, James, Kirwan, Cliona C, Johnson, Richard, Patel, Krupali, Ribas, Maria Dalmau, Vigneswaran, Natali, Challoner, Tom, Park, Alan, Rizkalla, Maged, Tomlins, Abigail, McEvoy, Kat, Jafferbhoy, Sadaf, Soumian, Soni, Narayanan, Sankaran, Kirby, Robert, Bajrusevic, Sladana, Maalo, Joseph, Charalambous, Michalis, Lai, Lee Min, Chong, Kelvin, Thomson, Simon, Monib, Sherif, Chagla, Leena, Audisio, Riccardo, Taghizadeh, Rieka, Iqbal, Azhar, James, Karen, Callaghan, Maria, Poonawala, Shabbir, Lund, Jonathan, Vinayagam, Raman, Thrush, Steven, Thomas, Rachel Bright, Mullan, Michelle, Taylor, Jevan, Yoshimura, Ryo, Mathew, Tom, Jones, Ben Mancey, Munot, Kailas, Nasr, Rana, Piper, Jenny, El-Sharief, Deena, Mustafa, Mohammed, Dumitru, Dorin, Christopoulos, Petros, O'Leary, Peter, Athanasiou, Irene, Johns, Neil, Mehta, Disha, Bibi, Saira, Syed, Farah, Koris, Jacob, Healy, Samuel, Shanks, Lindsay, Oliver, James, Bucata, Claudiu, Clarke, Natalie, Bignell, Kym, Akerlund, Malin, Brock, Lisa, Hallam, Kelly, Howes, Rachel, Armstrong, Alexander, Sethu, Claire, Zeidan, Bashar, Sjokvist, Olivia, Tasoulis, Marios, Sundaramoorthy, Souganthy, Harris, Chad, Wintrip, Dorothy, Lymperopoulos, N, Jain, Yogesh, Balata, Safa Ahmed, Grp, iBRA-2 Steering, and Collab, Breast Reconstruction Res
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,Mammaplasty ,trainee collaboratives ,Breast Neoplasms ,Article ,Cohort Studies ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Breast cancer ,breast cancer ,Adjuvant therapy ,cohort study ,Medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Mastectomy ,Aged ,Cancer ,Aged, 80 and over ,Manchester Cancer Research Centre ,business.industry ,ResearchInstitutes_Networks_Beacons/mcrc ,adjuvant therapy ,immediate breast reconstruction ,Middle Aged ,medicine.disease ,Surgery ,Radiation therapy ,Oncology ,Centre for Surgical Research ,Chemotherapy, Adjuvant ,Outcomes research ,030220 oncology & carcinogenesis ,Surgical oncology ,Female ,Breast reconstruction ,business ,Complication ,Cohort study - Abstract
Background: Immediate breast reconstruction (IBR) is routinely offered to improve quality-of-life for women requiring mastectomy, but there are concerns that more complex surgery may delay adjuvant oncological treatments and compromise long-term outcomes. High-quality evidence is lacking. The iBRA-2 study aimed to investigate the impact of IBR on time to adjuvant therapy.Methods: Consecutive women undergoing mastectomy ± IBR for breast cancer July–December, 2016 were included. Patient demographics, operative, oncological and complication data were collected. Time from last definitive cancer surgery to first adjuvant treatment for patients undergoing mastectomy ± IBR were compared and risk factors associated with delays explored.Results: A total of 2540 patients were recruited from 76 centres; 1008 (39.7%) underwent IBR (implant-only [n = 675, 26.6%]; pedicled flaps [n = 105,4.1%] and free-flaps [n = 228, 8.9%]). Complications requiring re-admission or re-operation were significantly more common in patients undergoing IBR than those receiving mastectomy. Adjuvant chemotherapy or radiotherapy was required by 1235 (48.6%) patients. No clinically significant differences were seen in time to adjuvant therapy between patient groups but major complications irrespective of surgery received were significantly associated with treatment delays.Conclusions: IBR does not result in clinically significant delays to adjuvant therapy, but post-operative complications are associated with treatment delays. Strategies to minimise complications, including careful patient selection, are required to improve outcomes for patients.
- Published
- 2019
18. Variation in the provision of breast reconstruction and contralateral mastectomy in patients with unilateral breast cancer in England: A population cohort study.
- Author
-
Johnson, Leigh, Brunsden, Sam, Fairhurst, Katherine, and Potter, Shelley
- Subjects
MAMMAPLASTY ,BREAST cancer ,MASTECTOMY ,COHORT analysis - Published
- 2024
- Full Text
- View/download PDF
19. Exploring information provision in reconstructive breast surgery: A qualitative study.
- Author
-
Potter, Shelley, Mills, Nicola, Cawthorn, Simon, Wilson, Sherif, and Blazeby, Jane
- Subjects
BREAST surgery ,PLASTIC surgery ,MEDICAL decision making ,MEDICAL personnel ,HEALTH outcome assessment - Abstract
Objective Women considering reconstructive breast surgery (RBS) require adequate information to make informed treatment decisions. This study explored patients' and health professionals' (HPs) perceptions of the adequacy of information provided for decision-making in RBS. Methods Semi-structured interviews with a purposive sample of patients who had undergone RBS and HPs providing specialist care explored participants' experiences of information provision prior to RBS. Results Professionals reported providing standardised verbal, written and photographic information about the process and outcomes of surgery. Women, by contrast, reported varying levels of information provision. Some felt fully-informed but others perceived they had received insufficient information about available treatment options or possible outcomes of surgery to make an informed decision. Conclusions Women need adequate information to make informed decisions about RBS and current practice may not meet women's needs. Minimum agreed standards of information provision, especially about alternative types of reconstruction, are recommended to improve decision-making in RBS. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
20. P114. The clinical impact and resource implication of her-2 testing in breast cancer patients 80 and over: A multi-centre retrospective study.
- Author
-
Chambers, Alice, Cohen, Hugo, Merker, Louise, Bright-Thomas, Rachel, Potter, Shelley, and Mullan, Michelle
- Subjects
BREAST cancer ,CANCER patients ,RETROSPECTIVE studies - Published
- 2021
- Full Text
- View/download PDF
21. 04. ARE WE OVERTREATING BREAST CANCERS FOLLOWING PREVIOUS BREAST AUGMENTATION? LESSONS FROM IBRA.
- Author
-
Baker, Benjamin, Harvey, James, and Potter, Shelley
- Subjects
BREAST cancer ,BREAST ,MAMMAPLASTY ,AUGMENTATION mammaplasty ,WOUND infections - Abstract
B Introduction: b Bilateral breast augmentation (BBA) remains the most commonly performed cosmetic operation in the UK, but there is no consensus regarding the surgical management of these patients that subsequently develop breast cancer. B Method: b Patients were identified from the Implant-based Breast Reconstruction Audit (iBRA) database, a prospective, multi-centre cohort study recruiting consecutive women who had any type of immediate IBR following mastectomy at 81 UK units February 2014-June 2016. Patients were younger, lower BMI, had smaller tumours, and were more likely to have undergone risk reducing surgery than the overall iBRA cohort. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
22. Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study
- Author
-
Jamie J Kirkham, Ellen Copson, Baek Kim, Shelley Potter, Charlotte E. Coles, Nisha Sharma, Elizabeth Camacho, Kieran Horgan, Stuart McIntosh, Daniel R. Leff, Rachel O'Connell, Rajiv V. Dave, Chris Holcombe, Ramsey I. Cutress, Patricia Fairbrother, Christopher W. J. Cartlidge, Ashu Gandhi, Vicky P. Taxiarchi, Alona Courtney, Tim Rattay, Raghavan Vidya, Cliona C. Kirwan, Dave, Rajiv V. [0000-0001-6827-8090], McIntosh, Stuart A. [0000-0002-4123-9611], Potter, Shelley [0000-0002-6977-312X], Copson, Ellen [0000-0001-8994-4056], Apollo - University of Cambridge Repository, Cancer Research UK, Dave, Rajiv V [0000-0001-6827-8090], and McIntosh, Stuart A [0000-0002-4123-9611]
- Subjects
Cancer Research ,692/700/784 ,medicine.medical_treatment ,Cohort Studies ,0302 clinical medicine ,Breast cancer ,Quality of life ,Surgical oncology ,Pandemic ,Epidemiology ,030212 general & internal medicine ,692/700/1538 ,Aged, 80 and over ,Covid19 ,health policy ,Middle Aged ,Health care economics ,Health policy ,Oncology ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,Female ,Breast reconstruction ,Life Sciences & Biomedicine ,B-MaP-C study collaborative ,Cohort study ,Adult ,medicine.medical_specialty ,Breast Neoplasms ,Article ,1117 Public Health and Health Services ,692/4028/546 ,surgical oncology ,03 medical and health sciences ,breast cancer ,SDG 3 - Good Health and Well-being ,medicine ,Humans ,1112 Oncology and Carcinogenesis ,692/700/3934 ,Oncology & Carcinogenesis ,Aged ,Science & Technology ,business.industry ,SARS-CoV-2 ,COVID-19 ,health care economics ,medicine.disease ,Radiation therapy ,quality of life ,Emergency medicine ,692/4028/67/1347 ,business - Abstract
Background The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. Methods This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting. Findings Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. Conclusions The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.